Genomes.io Joins Tachyon 2.0: ConsenSys Ventures Blockchain-Focused Accelerator

Monday, April 1, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

BERLIN, April 1, 2019 /PRNewswire/ -- Genomes.io, the London-based startup using blockchain

technology to give people ownership and control over their genomic data, arrives at the German Bundestag in Berlin for the kickoff of Tachyon 2.0 - the accelerator program run by the world-leading blockchain company ConsenSys
Ventures. Genomes.io feature as the only health technology company accepted into Tachyon 2.0 alongside 10 other companies from across the globe.

Tachyon 2.0 is focused on building new blockchain-enabled solutions and platforms across data privacy and identity, advanced encryption, healthcare, AI and IoT solutions, decentralized finance, microinsurance and other sectors. It features programming time spent in global blockchain hubs of Berlin and San Francisco in which Genomes.io will benefit from meetings and lectures with prominent entrepreneurs, Ethereum developers and venture capitalists — as well as access to ConsenSys' vast and diverse network.

Aldo de Pape, CEO of Genomes.io, said, "We are honoured to have been invited to join the Tachyon 2.0 cohort. We believe the technical, industrial expertise and backing of ConsenSys will significantly bolster our efforts to power personalised medicine by building the Web 3.0 solution for the secure storage and private sharing of genomic data that gives ownership and control back to the individual."

Kavita Gupta, managing partner of ConsenSys Ventures, said, "We continue believing in providing support to promising entrepreneurs that need the accelerator format to refine their projects and ideas. With the backing of the ConsenSys and Ethereum ecosystems, we aim to provide all the necessary tool-kits for our entrepreneurs to succeed both in the short term and in the long run."

Genomes.io acceptance into the accelerator follows a successful Crowdcube raise in 2018 which attracted investment from over 300 investors.

About Genomes.io

Genomes.io is a DNA data bank that uses blockchain and encryption technologies to allow users to query and share segments of their genome using a repeat consent model. Genomes.io offers a secure and private DNA sequencing, storage and sharing solution that brings together individuals (data owners) and research organisations (data buyers) to power a more equitable move towards personalised medicine.

About Tachyon

Tachyon is the first-ever blockchain-focused accelerator created by Consensys Ventures that backs the most promising startups building on Ethereum across three main tracks: blockchain for-profit, open source and social impact projects.

About ConsenSys Ventures                        

ConsenSys Ventures is the external investment arm of ConsenSys that invests in pre-seed and seed-stage Ethereum projects across the Web 3.0 stack. Sector and geography agnostic, ConsenSys Ventures is building a circular economy where companies feed into one another while supporting the broader Ethereum ecosystem. ConsenSys Ventures aims to tie the existing Web 2.0 to the emerging Web 3.0 stack. For more information, please visit https://consensys.vc.

About ConsenSys

ConsenSys is transforming our present digital architecture toward a more open, inclusive and secure internet of value, commonly called Web3. With a more trustworthy internet architecture, we are helping individuals, enterprises and governments unlock new business models and value, gain efficiencies through a shared IT infrastructure and utilize cutting-edge cryptographic methods to safeguard private user data. We accomplish this through our unique global business developing the Ethereum blockchain, comprised of a startup incubator, Enterprise Ethereum consulting arm and investment fund.

Media Enquiries Contact:Aldo De Papealdo@genomes.io

Cision View original content:http://www.prnewswire.com/news-releases/genomesio-joins-tachyon-2-0-consensys-ventures-blockchain-focused-accelerator-300821520.html

SOURCE Genomes.io



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store